Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 March 2025
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over (TA1033)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 February 2025
Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 March 2023
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 July 2022
Cenobamate for treating focal onset seizures in epilepsy (TA753)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2021
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sulthiame for treating self-limiting epilepsy with centrotemporal spikes in children TSID 12106Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC